TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be at least 18 years of age~* Have histologically or cytologically-confirmed malignant disease in an advanced incurable stage~* Have not received chemotherapy or radiation for \>14 days (advanced cancer patients receiving hormonal therapy or targeted therapy that does not come with a recommendation for prophylactic anti-emetic therapy are eligible)~* Have chronic nausea that has been present for at least one week (worst daily score \>3, 0-10 visual analogue scale) or vomiting at least five times over past one week~* Have serum creatinine \< 2.0 mg/dl and serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) \< 3 times upper limits of normal ≤120 days prior to registration~* Absolute neutrophil count (ANC) \>1500 mm3 \<120 days prior to registration~* Women of childbearing potential must consent to use adequate contraception throughout protocol therapy; females of childbearing potential must have a negative urine pregnancy test \<7 days prior to registration.~Exclusion Criteria:~* Not be receiving treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone for less than or equal to 30 days prior to registration or planned during protocol therapy (patients may have received prochlorperazine and other phenothiazines as prior anti-emetic therapy)~* Not have concurrent use of ethyol~* Not have severe cognitive compromise~* History of central nervous system (CNS) disease (e.g. brain metastases, seizure disorder)~* Concurrent use of amifostine, concurrent abdominal radiotherapy; concurrent use of quinolone antibiotic therapy~* Chronic alcoholism (as determined by the investigator)~* Known hypersensitivity to olanzapine~* Known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous six months~* History of uncontrolled diabetes mellitus (stable insulin dose and/or stable oral hypoglycemic agent permitted)~* Planned chemotherapy or radiation during the 7 days following study initiation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: EXPERIMENTAL): Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive a placebo orally for 1 to 7 days daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has a history of migraine (according to The International Classification of Headache Disorders, third edition \[beta version\] criteria) or clinical judgment suggests a migraine diagnosis~* Patient fulfills the criteria for Episodic migraine in baseline information collected during the 28 day screening period~* Not using preventive migraine medications for migraine or other medical conditions or using no more than 1 preventive migraine medication for migraine or other medical conditions if the dose and regimen have been stable for at least 2 months prior to giving informed consent.~* Patient demonstrates compliance with the electronic headache diary during the screening period by entry of headache data on a minimum of 24 of 28 days and the entered data is judged appropriate by the investigator.~Exclusion Criteria:~Patients who have previously failed (lack of efficacy) 2 or more of the clusters of the medications for treatment of migraine after use for at least 3 months at accepted migraine therapeutic doses~- Hematological, cardiac, renal, endocrine, pulmonary, gastrointestinal, genitourinary, neurologic, hepatic, or ocular disease considered clinically significant in the judgment of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TEV-48125 (225/225/225 mg) group (Type: EXPERIMENTAL): TEV-48125 will be subcutaneously administered once monthly for 3 months (225/225/225 mg).
- TEV-48125 (675 mg/placebo/placebo) group (Type: EXPERIMENTAL): TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/placebo/placebo).
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Children under 14 years of age with RRD undergoing primary repair Preoperative PVR grade B or higher High risk RRD: uveitis; large, giant, or multiple tears; vitreous hemorrhage; preoperative choroidal detachments; aphakia; and large detachments involving greater than two quadrants of the eye~Exclusion Criteria:~Children with RRD related to penetrating ocular trauma involving the posterior segment Previous RD repair surgery Uncontrolled glaucoma or other concomitant ocular morbidities Patients with bleeding diathesis, hepatic and renal failure Corneal opacity sufficient to impair surgical view No light perception vision Inability to complete follow-up

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Group A received intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml) during pars plana vitrectomy and silicone oil injection with scleral buckle in children under 14 years of age with high-risk PRRD
- Control group (Type: PLACEBO_COMPARATOR): Group B received infusion of normal saline during pars plana vitrectomy and silicone oil injection with scleral buckle in children under 14 years of age with high-risk PRRD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Wearable Pulsed Electromagnetic Fields Device in Knee Osteoarthritis: Double Blinded, Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a diagnosis of primary OA of the knee according to the ACR criteria, including radiologic evidence of OA~* age \>40 years~* symptomatic disease for at least 6 months prior to enrollment~* persistent pain despite receiving the maximum tolerated doses of conventional medical therapy, including acetaminophen (4 gm/day) and/or a nonsteroidal antiinflammatory drug (NSAID), with persistent pain defined as a minimum mean score of 25 mm on the visual analog scales (VAS) for global pain (0-100-mm range for each) daily pain during the month prior to study enrollment~* ability to attend followup appointments~Exclusion Criteria:~* secondary causes of OA~* local or systemic infection~* diabetes mellitus~* systemic arthritis~* allergy to anesthetic agent or contrast material~* coagulopathy~* anticoagulant therapy~* had previous IA steroid injection~* avascular necrosis of bone~* patients who are on specific OA pharmacological therapy (NSAIDS, opioids) for more than 2 weeks prior enrollment

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- active (Type: ACTIVE_COMPARATOR): Group wearing the active device emitting pulsed electromagnetic fileds
- placebo (Type: PLACEBO_COMPARATOR): Group wearing the device non-emitting pulsed electromagnetic fileds

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Patient Benefits With a New Supporting Ostomy Product in Patients With a Newly Stoma Formation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Have provide written informed consent.~2. Be at least 18 years of age and have full capacity.~3. Have had their stoma for less than 9 months.~4. Have intact skin on the peristomal area (assessed by investigator)~5. Be able to use one of the five test products (i.e. Ø40, Ø50, Ø60, Ø70, Ø80 mm)~6. Ileo- or colostomists with liquid and/or mushy output (Bristol scale type 5-7)~7. Is willing to refrain from use of paste and protective sheets.~8. Have a smartphone applicable for the HeyloTM app.~9. Have been self-managing stoma appliance for at least 14 days.~10. Are able to follow study procedures for 3 months (assessed by investigator)~11. Are willing to receive their ostomy products through Coloplast Charter for the duration of the study.~Exclusion Criteria:~1. Currently receiving or have within the past month received topical steroid treatment in the peristomal skin area or systemic steroid (tablet/injection) treatment.~2. Is breastfeeding.~3. Is pregnant based on urine pregnancy test.~4. Enrolled in another current research study or have previously participated in this investigation.~5. Has known hypersensitivity towards any of the products used in the investigation.~6. Is using/have a pacemaker.~7. Has a complicated stoma at baseline (dehiscence/prolapse/hernia)~8. Has limited life expectancy or receive palliative care.~9. Has stage 4 cancer.~10. Having more than one stoma synchronously~11. Having ongoing non-healed abdominal wounds~12. Reoperation / stoma reversal planned during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test product - new supporting ostomy product and support service (Type: OTHER): The arm includes the newly developed supporting ostomy product (leakage notification system Heylo) used together with a support service

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 and older~* Diagnosis of schizophrenia or schizoaffective disorder~* Known to have medication treatment adherence problems as identified by the TRQ (20% or more missed medications in past week or past month)~* Ability to be rated on psychiatric rating scales~* Willingness to take long-acting injectable medication~* Able to provide written, informed consent to study participation~Exclusion Criteria:~* History of allergy or intolerance to haloperidol or haloperidol decanoate~* Individuals on long-acting injectable antipsychotic medication immediately prior to study enrollment~* Medical condition or illness, which in the opinion of the research psychiatrist, would interfere with the patient's ability to participate in the trial~* Physical dependence on substances (alcohol or illicit drugs) likely to lead to withdrawal reaction during the course of the study in the clinical opinion of the treated research psychiatrist~* Immediate risk of harm to self or others~* Female who is currently pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CAE + LAI (Type: EXPERIMENTAL): Customized Adherence Enhancement (CAE) + Long-Acting Injectable Antipsychotic (LAI)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma~* Unresectable and recurrent gastric cancer~* Age 20 to 74~* Performance status 0, 1, or 2 (ECOG)~* Life expectancy 3 months~* No prior chemotherapy or radiotherapy for gastric cancer~* Able to take oral medication~* Evaluable or not evaluable lesion had already checked more than 28 days before participated in this study~* Hematopoietic Absolute granulocyte count lower limit of normal-12,000/mm\^3 Platelet ≥ 100,000/mm\^3 Hemoglobin ≥ 8.0 g/dL~* Hepatic AST and ALT ≤ 100 U/L ALP ≤ 2 times upper limit of normal (ULN) Bilirubin ≤ 1.5 mg/dL~* Renal Plasma creatinine ≤ ULN Creatinine clearance ≥ 50 mL/min~Exclusion Criteria:~* Pregnant or nursing~* Bleeding from gastrointestinal tract or no diarrhea~* Hypersensitivity to TS-1 or CDDP~* Psychiatric disorder that would preclude study compliance or giving informed consent~* Severe acute or chronic medical or psychiatric condition or laboratory abnormality~* Serious illness or medical condition~* Brain metastasis~* Ascites requiring drainage

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): TS-1 and cisplatin
- 2 (Type: ACTIVE_COMPARATOR): TS-1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have undergone a heart transplantation and who receive their routine care at the Morgan Stanley Children's Hospital of New York, Columbia University Medical Center~Exclusion Criteria:~* Patients admitted to the inpatient heart failure team~* Patients present for their first outpatient catheterization after new transplant~* Abnormal hemodynamics concerning for acute rejection~* Patients present for follow up of rejection (last biopsy positive)~* Ingested methylxanthine-containing foods that day~* Patients taking oral dipyridamole and did not discontinue it 3 days prior to testing~* Prior transplant history of coronary artery vasculopathy with this allograft or concern for abnormal coronary vasculature by angiography on the day of the catheterization~* Patients taking carbamazepine (may potentiate adenosine effect)~* Patients with known conduction disease (first, second or third degree atrioventricular block) and/or with pre-existing sinus node dysfunction (based on pre-existing ECG, Holter or inpatient telemetry)~* Patients/guardians unable to give consent in English

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Adenosine (Type: EXPERIMENTAL): After cardiac catheterization, the study protocol will begin with 12.5µg/kg of adenosine (one eighth the recommended starting clinical dose), and will double to 25µg/kg, 50µg/kg, 100µg/kg and finally 200µg/kg (not to surpass the total maximum dose of 12mg). A pacing catheter will be placed within the right ventricle prior to medication administration. Escalating doses will stop if ventricular pacing is required due to a ventricular pause greater than 12 seconds or if atrioventricular block is demonstrated with a ventricular pause less than 12 seconds. If there is no prolonged pause requiring pacing and no demonstration of medication effect the subsequent dose will be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Valproate in Late Life Schizophrenia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have a diagnosis of schizophrenia as confirmed by the MINI~* Must be on antipsychotic medication~* Must be age 50 year or older~* Must be capable of providing written informed consent for study participation. In situations where individuals have guardians of person, guardian and subject must both provide written consent; and~* Must live in the Northeast Ohio area.~Exclusion Criteria:~* A primary psychiatric DSM Axis I diagnosis other than schizophrenia~* Actively abusing substances; or~* Medically unstable.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- valproate (Type: EXPERIMENTAL): All participants received open-label, add-on valproate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have a diagnosis of T2DM and be currently treated with metformin and sulphonylurea~* Patients in the study must have a HbA1c between \>=7 and \<=10.5%~* Patients must have a fasting plasma glucose (FPG) \<270 mg/dL (15 mmol/L)~Exclusion Criteria:~* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
- Canagliflozin 300 mg (Type: EXPERIMENTAL): Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive matching placebo once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immigrant Well-being Project: Transdisciplinary Ecological Mental Health Intervention for Mexican Immigrants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Mexican immigrant~* Residing in Bernalillo County, New Mexico~Exclusion Criteria:~* Severe cognitive functioning problems~* Imminent suicide risk~* Mental illness that is so severe as to impede participation in a group and that warrants immediate individual treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Immigrant Well-being Project Intervention (Type: OTHER): Intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Overactive bladder~* Clinical diagnosis of Postmenopausal:~* English language skills sufficient to complete questionnaires~* Clinical indication for vaginal estrogen use~* Not currently receiving vaginal estrogen therapy~Exclusion Criteria:~* Currently on systemic hormone replacement therapy (HRT) Have been on HRT within the past three months~* Clinical diagnosis of estrogen dependent malignancies~* Allergy to local estrogen therapy~* Insufficient language skills to complete study questionnaires~* Women with active, urinary tract infection~* Received antibiotics within the past two weeks~* Clinical diagnosis of stage 3 or 4 pelvic organ prolapse~* Patient unwilling to use vaginal estrogen preparation~* Currently on anticholinergic medication Have received anticholinergic medication within the past three months~* Previously failed two medications for treatment of OAB Previously received intra-vesicle botulinum toxin injections Previously had posterior tibial nerve stimulation Previously had implantation of sacral neuromodulator~* Patients wishing to start anticholinergic medication at the initial encounter~* Undiagnosed abnormal genital bleeding~* Clinical diagnosis of deep vein thrombosis (DVT) Clinical diagnosis of pulmonary embolism (PE)~* Clinical diagnosis of arterial thromboembolic disease~* Clinical diagnosis of liver dysfunction or disease~* Clinical diagnosis of protein C, protein S or antithrombin or deficiency other known thrombophilic disorders

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- conjugated estrogen (Type: OTHER): All patients in the study will receive 0.625 mg conjugated estrogen/gram to use 0.5 grams twice weekly with the applicator for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete